Phibro Animal Health Corporation (NASDAQ:PAHC) Q3 2024 Earnings Call Transcript

Larry Miller: It’s Larry. On the second part of your question, the Zoetis MFA business actually has a significant weighting of products that are not considered medically important for human medicine by the World Health Organization. These include ionophores, no products in this class are used in human medicine. Anticoccidials, no products in this class are used in human medicine. And the bacitracins are regarded — are not regarded as medically important. Therefore, the combined Zoetis MFA and Phibro portfolios of Medicated Feed Additives Nutrition Specialties and Vaccines offer several choices to livestock producers including those who produce an antibiotic-free and/or no antibiotics use in human medicine. As to your question about the poultry industry and some of the changes we’ve seen there however, it refers to the reintroduction of ionophores, which again are not medically important antimicrobials.

They are used to control coccidiosis and other enteric diseases. Phibro does not currently have ionophores in the US. So we really haven’t seen impact on our business. However, the Zoetis MFA business does contain ionophores which will allow us to serve customers with the — with products in this — in this class.

Balaji Prasad: Thank you.

Operator: And that will conclude our question-and-answer session. I’ll hand the call back to Glenn David for any closing remarks.

Glenn David: Thank you, Regina and thank you everyone for listening in to today’s call. We really appreciate your time attention.